Mitigating Adverse Event Reporting Bias in Spine Surgery

被引:11
作者
Auerbach, Joshua D. [1 ]
McGowan, Kevin B. [2 ]
Halevi, Marci [3 ]
Gerling, Michael C. [4 ]
Sharan, Alok D. [5 ]
Whang, Peter G. [6 ]
Maislin, Greg [7 ]
机构
[1] Bronx Lebanon Hosp Ctr, Albert Einstein Coll Med, Dept Orthopaed, Bronx, NY 10457 USA
[2] Musculoskeletal Clin Regulatory Advisers, Dept Regulatory Affairs, Washington, DC 20005 USA
[3] Paradigm Spine LLC, New York, NY 10022 USA
[4] Lutheran Med Ctr, Dept Surg, Spine Div, Brooklyn, NY 11220 USA
[5] Albert Einstein Coll Med, Dept Orthopaed Surg, Bronx, NY 10467 USA
[6] Yale Univ, Sch Med, Dept Orthopaed & Rehabil, New Haven, CT 06520 USA
[7] Biomed Stat Consulting, Wynnewood, PA 19096 USA
关键词
BONE MORPHOGENETIC PROTEIN-2; LUMBAR INTERBODY FUSION; RADIOGRAPHIC OUTCOMES; OF-INTEREST; RHBMP-2; TRIALS; ARTHRODESIS; INTEGRITY; CONFLICT; INDUSTRY;
D O I
10.2106/JBJS.L.00251
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Background: Recent articles in the lay press and literature have raised concerns about the ability to report honest adverse event data from industry-sponsored spine surgery studies. To address this, clinical trials may utilize an independent Clinical Events Committee (CEC) to review adverse events and readjudicate the severity and relatedness accordingly. We are aware of no prior study that has quantified either the degree to which investigator bias is present in adverse event reporting or the effect that an independent CEC has on mitigating this potential bias. Methods: The coflex Investigational Device Exemption study is a prospective randomized controlled trial comparing coflex (Paradigm Spine) stabilization with lumbar spinal fusion to treat spinal stenosis and spondylolisthesis. Investigators classified the severity of adverse events (mild, moderate, or severe) and their relationship to the surgery and device (unrelated, unlikely, possibly, probably, or definitely). An independent CEC, composed of three spine surgeons without affiliation to the study sponsor, reviewed and reclassified all adverse event reports submitted by the investigators. Results: The CEC reclassified the level of severity, relation to the surgery, and/or relation to the device in 394(37.3%) of 1055 reported adverse events. The proportion of adverse events that underwent reclassification was similar in the coflex and fusion groups (37.9% compared with 36.0%, p = 0.56). The CEC was 5.3 (95% confidence interval [Cl], 2.6 to 10.7) times more likely to upgrade than downgrade the adverse event. The CEC was 7.3 (95% Cl, 5.1 to 10.6) times more likely to upgrade than downgrade the relationship to the surgery and 11.6 (95% Cl, 7.5 to 18.8) times more likely to upgrade than downgrade the relationship to the device. The status of the investigator's financial interest in the company had little effect on the reclassification of adverse events. Conclusions: Thirty-seven percent of adverse events were reclassified by the CEC; the large majority of the reclassifications were an upgrade in the level of severity or a designation of greater relatedness to the surgery or device.
引用
收藏
页码:1450 / 1456
页数:7
相关论文
共 31 条